Mark Figgie, M.D. has been named WishBone Medical, Inc.’s interim chief executive officer amid the company’s recent receipt of additional growth capital.
Dr. Mark Figgie Interim WishBone CEO Amid New Funding
2 min read Premium comments
Secondary#wishbonemedical
Dr. Figgie is currently a board member and surgeon advisor at WishBone, a pediatric orthopedic company based in Warsaw, Indiana. He is considered an expert in the field of joint replacement for inflammatory arthritis. Dr. Figgie is also chief emeritus of the surgical arthritis service at the Hospital for Special Surgery. In that role, he oversees the care of patients with systemic diseases.
Manny Losada serves on the WishBone Board of Directors and is the CEO and president of Optimal/MedPro Healthcare Solutions. Losada commented, “WishBone constituents may know Dr. Figgie for his advocacy as a foundational board member, investor, and his 40 years of exemplary experience in orthopedics.”
Losada continued, “However, he also has an incredible business acumen grounded in an MBA at NYU and managed a boutique manufacturing firm in Cleveland, OH, while attending medical school. Dr. Figgie will work alongside the seasoned executive management team and surgeons to create leading-edge solutions that kids deserve.”
OTW spoke with Dr. Figgie about his new appointment: “As a surgeon advisor, I’ve grown well acquainted with several WishBone employees over the years. As I meet and work alongside others in the office, my first impression of this team is confirmed: They are truly here to help kids.”
Dr. Figgie continued, “Throughout the organization, people of different backgrounds and skill sets are united by a shared vision. They show up each day with an open, problem-solving mindset—driven to improve the lives of pediatric patients. I look forward to furthering my contributions to this cause, fostering close relationships with other surgeons and supporting the daily operations of our team, as we continue to develop unique products for children.”
WishBone CEO, Chairman, and Co-Founder Nick Deeter is moving away from his position as CEO of the company. Additionally, WishBone President, Board Member, and Co-Founder Mary Wetzel is also stepping away from her position as president of the company. The two will move “into consulting roles to assist in business development, healthcare partnerships, and identification of new technology ventures.”
The new funding comes from LKCM Headwater Investments, a Fort Worth, Texas-based private investment firm. The firm is affiliated with Luther King Capital Management, an SEC-registered investment firm.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.